Fig. 2From: Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placeboTime to initial FACIT-F total score response: a OPAL Broaden, b OPAL Beyond (FAS). Response defined for FACIT-F total score as ≥ 4-point improvement from baseline. BID, twice daily; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; Q2W, once every 2 weeks; SC, subcutaneousBack to article page